| Today's Top Story |  |  | | - Opexa licenses MS T-cell therapy to Merck Serono for up to $225M
Merck Serono has signed a deal with Opexa Therapeutics for the option to acquire exclusive development and marketing rights to Opexa's Tcelna, or imilecleucel-T, an experimental personalized T-cell treatment for multiple sclerosis, in all countries except Japan. Opexa received $5 million upfront, and would get an additional $25 million or $15 million if Merck exercises the option. Opexa is also eligible to receive as much as $195 million in milestone fees plus sales royalties. Genetic Engineering & Biotechnology News (2/5)       | Health Care & Policy | | | | - Talent gap threatens biopharma research
Pharmaceutical industry executives say they have had difficulty hiring top talent, a PricewaterhouseCoopers Health Research Institute survey of CEOs found. One-third of U.S. biopharmaceutical companies have tried novel approaches to filling research and development staffing needs, including: revamping their R&D operations; narrowing focus areas; and partnering with contract research organizations, competitors, foundations or academic institutions. Researchers will increasingly need skills in developing and managing outside partnerships, an understanding of regulatory science, and knowledge of bioinformatics and health economics, biopharma CEOs say. PharmaTimes (U.K.) (2/5) - Sanofi-Regeneron's Zaltrap wins EU approval for colon cancer
The European Commission approved the use of Sanofi and Regeneron Pharmaceuticals' Zaltrap, or aflibercept, in combination with irinotecan, 5-fluorouracil and leucovorin to treat patients with metastatic colorectal cancer who don't respond to an oxaliplatin-containing treatment regimen. The decision was based on the VELOUR study, which showed that combining Zaltrap with chemotherapy significantly prolonged survival. PharmaTimes (U.K.) (2/5) - FDA seeks more data on Hemispherx's Ampligen
The FDA didn't approve Hemispherx Biopharma's application for its candidate chronic fatigue syndrome drug Ampligen. The drugmaker will seek an "end-of-review" meeting with regulators and could file a formal appeal. Hemispherx said the agency requested data analyses, the completion of nonclinical trials and at least one more study involving patients. Reuters (2/4) - StemEx lowers mortality rate in patients with blood cancers
Gamida Cell said a late-stage clinical trial found its allogeneic stem cell treatment, StemEx, can reduce mortality rates among leukemia and lymphoma patients. The death rate 100 days after StemEx treatment was 15.8%, compared with 24.5% for those treated with two double cord umbilical blood transplants. Globes (Israel) (2/4) | Company & Financial News | | | | - J&J's Janssen Labs welcomes individual life sciences entrepreneurs
Janssen Labs, the Johnson & Johnson business accelerator program, will welcome individual life sciences entrepreneurs to join the innovation center, after working with 18 early-stage companies since it opened last year. Jansen's "concept lab" is under development and will offer 10 workstations to be leased individually, and the lab is also creating shared office space that can accommodate 20 people for use not just by scientists but in the pursuit of financing and partnerships. Xconomy (2/5) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Austria's Andritz to equip Brazilian cellulosic ethanol project
Austria-based Andritz expects to formalize a deal this month to provide equipment to a $40 million demonstration-scale cellulosic ethanol plant that Brazilian research agency Centro de Tecnologia Canavieira will develop in Sao Manoel. Finland's Poyry Oyj will begin building the plant in July, with production expected to begin mid-2014, said Robson Cintra de Freitas, CTC's director of business and new technology. Bloomberg Businessweek (2/5)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | I've learned that people will forget what you said, people will forget what you did, but people will never forget how you made them feel."
--Maya Angelou,
American author and poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, February 05, 2013
- Monday, February 04, 2013
- Friday, February 01, 2013
- Thursday, January 31, 2013
- Wednesday, January 30, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment